Regulatory Compliance Strategy Development

𝗛𝗲𝗿𝗲'𝘀 𝗺𝘆 𝟳-𝘀𝘁𝗲𝗽 𝗽𝗹𝗮𝘆𝗯𝗼𝗼𝗸 𝗳𝗼𝗿 𝗲𝗻𝘀𝘂𝗿𝗶𝗻𝗴 𝘀𝗺𝗼𝗼𝘁𝗵 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻𝘀 𝘁𝗵𝗮𝘁 𝗜'𝘃𝗲 𝗿𝗲𝗳𝗶𝗻𝗲𝗱 𝗼𝘃𝗲𝗿 𝘆𝗲𝗮𝗿𝘀 𝗶𝗻 𝘁𝗵𝗲 𝗠𝗲𝗱𝗧𝗲𝗰𝗵 𝗾𝘂𝗮𝗹𝗶𝘁𝘆 𝗮𝗻𝗱 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝗽𝗮𝗰𝗲: 𝟭. 𝗦𝘁𝗮𝗿𝘁 𝘄𝗶𝘁𝗵 𝘁𝗵𝗲 𝗲𝗻𝗱 𝗶𝗻 𝗺𝗶𝗻𝗱 - 𝟭𝟴-𝟮𝟰 𝗺𝗼𝗻𝘁𝗵𝘀 𝗯𝗲𝗳𝗼𝗿𝗲 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 • Map your regulatory strategy to your commercial goals • Identify your regulatory pathway early (510(k), De Novo, PMA) • Build testing protocols based on predicate devices when applicable 𝟮. 𝗗𝗲𝘀𝗶𝗴𝗻 𝘆𝗼𝘂𝗿 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗠𝗮𝗻𝗮𝗴𝗲𝗺𝗲𝗻𝘁 𝗦𝘆𝘀𝘁𝗲𝗺 𝗳𝗼𝗿 𝗲𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝗰𝘆 • Implement ISO 13485 principles from day one • Focus on the 7 critical SOPs that impact submissions most • Avoid the common trap of documentation overload (I've seen startups with 200+ SOPs when 35-40 would suffice) 𝟯. 𝗩𝗮𝗹𝗶𝗱𝗮𝘁𝗲 𝘆𝗼𝘂𝗿 𝘁𝗲𝘀𝘁𝗶𝗻𝗴 𝗺𝗲𝘁𝗵𝗼𝗱𝗼𝗹𝗼𝗴𝘆 𝗯𝗲𝗳𝗼𝗿𝗲 𝗲𝘅𝗲𝗰𝘂𝘁𝗶𝗻𝗴 • Pre-validate test methods with 3-5 pilot runs • Engage with testing labs that have FDA submission experience • Document protocol deviations properly (we found 63% of submissions get delayed due to inadequate deviation management) 𝟰. 𝗟𝗲𝘃𝗲𝗿𝗮𝗴𝗲 𝗽𝗿𝗲-𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗺𝗲𝗲𝘁𝗶𝗻𝗴𝘀 𝘀𝘁𝗿𝗮𝘁𝗲𝗴𝗶𝗰𝗮𝗹𝗹𝘆 • Schedule Q-Sub meetings 9-12 months before planned submission • Prepare focused questions (limit to a few critical issues) • Follow up with written summaries within the allocated time 𝟱. 𝗕𝘂𝗶𝗹𝗱 𝗮 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 "𝘄𝗮𝗿 𝗿𝗼𝗼𝗺" • Assemble cross-functional team (R&D, Clinical, Quality, Regulatory) • Create submission trackers with accountability metrics • Hold twice-weekly stand-ups in the 90 days before submission 𝟲. 𝗖𝗼𝗻𝗱𝘂𝗰𝘁 𝘁𝗵𝗶𝗿𝗱-𝗽𝗮𝗿𝘁𝘆 𝘀𝘂𝗯𝗺𝗶𝘀𝘀𝗶𝗼𝗻 𝗿𝗲𝘃𝗶𝗲𝘄 • Have external experts review 100% of your technical documentation • Use submission management platforms like RADAR or MasterControl • Schedule review 45-60 days before planned submission date 𝟳. 𝗣𝗿𝗲𝗽𝗮𝗿𝗲 𝗳𝗼𝗿 𝗶𝗻𝘁𝗲𝗿𝗮𝗰𝘁𝗶𝘃𝗲 𝗿𝗲𝘃𝗶𝗲𝘄 • Anticipate FDA questions with "pre-mortem" analysis • Have subject matter experts on standby during review period • Create response templates for common deficiency categories I learned these lessons the hard way. Early in my career I worked at a company where we had three submissions rejected due to inconsistent test data formatting. Now we use standardized data presentation templates that have cut our Additional Information requests by 72%. 𝗧𝗔𝗞𝗘𝗔𝗪𝗔𝗬: Regulatory success is about methodical preparation and strategic execution. The companies that view regulatory as a strategic function rather than a compliance burden consistently outperform their peers in time-to-market by an average of 7 months If you're preparing for an FDA submission in the next 12-18 months, I'd be happy to share our pre-submission checklist. Just message me directly

How Banks Ensure Regulatory Compliance: Conducting Treasury Activities Regulatory compliance is a cornerstone of modern banking, ensuring financial institutions operate within legal frameworks. For banks, particularly in treasury activities, maintaining compliance is crucial to uphold trust, manage risk, and avoid significant penalties. Here is how banks ensure regulatory compliance in their treasury operations: Understanding Regulatory Requirements: Banks must have a comprehensive understanding of relevant regulations, including international directives and national rules. These cover capital adequacy, liquidity management, and risk assessment. Robust Internal Controls: Implementing robust internal controls is essential. Compliance departments monitor and enforce adherence to regulatory standards through regular audits and reviews of treasury activities. Effective Risk Management: Banks use risk management frameworks to identify, assess, and mitigate risks in their treasury operations. This includes market risk, credit risk, and operational risk, maintaining a conservative approach. Training and Education: Continuous training ensures staff are aware of regulatory changes and understand their roles in compliance. Specialised training for treasury staff focuses on specific compliance requirements. Technology and Automation: Advanced software solutions monitor transactions, manage data, and generate compliance reports. These tools detect potential compliance issues in real-time for prompt corrective actions. Regular Reporting and Documentation: Accurate and timely reporting to regulatory bodies is essential. Comprehensive documentation of all treasury activities ensures transparency and provides a clear audit trail. Engagement with Regulators: Proactive engagement with regulators keeps banks informed about upcoming regulatory changes and provides guidance on compliance matters, addressing issues before they escalate. Scenario Analysis and Stress Testing: Conducting scenario analysis and stress testing helps ensure compliance under various market conditions. Banks assess the impact on their treasury activities to ensure they can withstand adverse conditions. Ensuring regulatory compliance in treasury activities is a multi-faceted process requiring understanding regulations, implementing robust controls, managing risks, continuous education, leveraging technology, accurate reporting, engaging with regulators, and conducting scenario analysis. By prioritising compliance, banks navigate the complexities of the regulatory landscape, contributing to the stability and integrity of the financial system.

A viral image of an ATM in Ludhiana recently caught my attention - a dangerously steep ramp ending abruptly at a glass door, with a staircase running alongside that leads nowhere. A perfect reminder of a hard-earned lesson in fintech: "Compliance isn’t just a checkbox." Product Managers: You don't want to miss saving 💾 this post for your future reference. This ramp was technically "compliant" - yes, there was a wheelchair access ramp. But it completely missed the purpose of accessibility. People had angry comments on social media about the apathy with which wheelchair-bound customers were treated and how the bank had made a mockery of accessibility. No amount of regulation can account for 'compliance as a checkbox' implementations that are designed to meet the regulation but not serve their intended purpose. It's the same trap I've seen countless fintech products fall into - implementing regulations as mere checkboxes rather than embracing them as design principles. I've experienced regulatory hurdles umpteen times in product launches; in fact, I've never experienced a straightforward implementation that hasn't hit a regulatory roadblock. BUT I can say this confidently: Compliance-first design is the secret sauce that makes the battle easier and less arduous, and inarguably 'faster' IF You just stick to the first principles of building this into your product strategy from day one . Regulations can either slow you down or become your competitive edge. To make compliance your strategic advantage, here's my 3-step playbook: 1/ Design Integration: Make regulatory adherence a natural part of the user experience rather than an afterthought ↳Embed compliance requirements into your initial product design ↳Get feedback from legal and compliance teams, and even the regulator if needed ↳Validate, Test, Iterate, Repeat 2/ Cross-Functional Collaboration: Build bridges between product, legal/compliance teams from day one ↳Involve them early ↳Make compliance & legal stakeholders brainstorm and provide feedback ↳Balance innovation with regulatory requirements using case studies and data to back up assertions instead of getting into crosshairs with them 3/ Validate Early, Validate Often: ↳Test with real scenarios ↳Get early feedback from regulators ↳Regular compliance assessments, no matter what stage of development you are in One golden tip - document everything, err on the side of caution when it comes to building and fostering trust with legal and compliance counterparts. The lesson in one line? Build WITH compliance, not around it. Instead of working around regulations, let's build with them. Because when you design within the right guardrails, innovation doesn't just survive—it scales. What's your strategy for managing fintech compliance? Share below. 👍 LIKE this post, 🔄 REPOST this to your network and follow me, Monica Jasuja

Building AI in regulated industries isn't about moving fast and breaking things. It's about moving thoughtfully while everything could break you. I just released a new Product Thinking with Melissa Perri Podcast episode that dives deep into this challenge featuring three guests who've navigated it firsthand: Dr. Maryam Ashoori, PhD from IBM Watson X, Magda Armbruster from Natural Cycles°, and Jessica Hall from Just Eat Takeaway.com. In healthcare, finance, and other regulated sectors, AI hallucinations aren't just bugs, they're compliance violations. When your product operates in environments where mistakes trigger audits, lawsuits, or regulatory action, the stakes fundamentally change how you build. Magda's insight hit me: bringing regulatory teams into product development early doesn't slow you down, it creates clarity. Instead of retrofitting compliance, you're designing with guardrails from day one. Maryam explained how this translates to AI agents that need human oversight at critical decision points. Jessica showed how to balance these constraints with unit economics and long-term capability building. The companies that get this right are turning regulatory excellence into competitive advantage. Clear processes, embedded compliance, and thoughtful AI deployment become your moat. Are you treating regulation as a roadblock or as a strategic differentiator in your AI strategy?

Build fast, but read the fine print faster Every founder wants to build fast. Speed is the oxygen of a #Startup. But there’s a reason oxygen tanks come with pressure valves— Because unregulated speed? It explodes. & nowhere is that truer than when it comes to #Compliance. Most founders treat compliance like a dentist appointment— Important. Uncomfortable. & something you push off… until it hurts. You’re moving fast, breaking things, pitching, building, shipping. Then one day... a #Regulator calls. Or worse—a lawsuit lands. Suddenly, you’re no longer the disruptor. You’re the defendant. ⚠️ If you touch money, data, or identity—you're already regulated You just don’t know it yet. & compliance isn’t a “later” problem. It’s a right-now-or-risk-everything problem. According to ComplyAdvantage: • 67% of high growth startups faced regulatory scrutiny by Series A • Another 23% faced enforcement actions that delayed funding, froze accounts, or triggered audits That’s 1 in 4 #Startups derailed because they didn’t read the fine print. 😬 The classic founder mistake? • MVP? ✅ • Pitch deck? ✅ • Fancy hoodies? ✅ • #ComplianceStrategy? ❌ • Regulatory exposure map? ❌❌ You don’t know what’s in the terms of your own API partner. You didn’t realize your onboarding flow violates 3 KYC requirements. You launched in a new region...but forgot to check if you’re even allowed to. & suddenly, that momentum you were scaling? It’s now evidence. Startups that treat compliance like an afterthought eventually find themselves running a company they no longer control. According to a 2023 McKinsey report, 43% of #fintech & #Web3 startups that scaled rapidly without regulatory alignment faced critical legal or operational slowdowns within 24 months. Some never recovered. Meanwhile, those that built compliance into their core strategy raised more capital, landed better partnerships, & stayed alive long enough to matter. Because compliance doesn’t slow you down—it keeps you from getting shut down. 👨💼 My advice to founders I’ve built & led startups across #RegulatedMarkets & here’s what I’ve learned: Compliance is either your moat or your mess. You choose. What I tell every founder I mentor: • If you're moving fast, move legally. You can’t scale trust after you’ve lost it. • Bring in a guardian architect early. Someone who spots the fine print before it becomes a lawsuit. • Don’t build on regulatory sand. That "quick win" you’re hacking together? If it’s not compliant, it’s a ticking time bomb. • Speak to #Regulators before they speak to you. They’re not enemies—but they are allergic to surprises. • Compliance isn’t what slows you down—it’s what keeps you in the race. 🏁 #Compliance is the cost of winning You can still be bold. You can still move fast. Just don’t be the founder who ignored the warning signs & built their startup like a house of cards—on a windy day. Build fast. But read the fine print faster. Because if you don’t…the lawyers will.

After reviewing hundreds of regulatory submissions at Complear, I've uncovered a shocking pattern that's costing the MedTech industry millions! 𝟖𝟎% 𝐨𝐟 𝐦𝐞𝐝𝐭𝐞𝐜𝐡 𝐬𝐭𝐚𝐫𝐭𝐮𝐩𝐬 𝐦𝐚𝐤𝐞 𝐭𝐡𝐞 𝐞𝐱𝐚𝐜𝐭 𝐬𝐚𝐦𝐞 𝐜𝐫𝐢𝐭𝐢𝐜𝐚𝐥 𝐦𝐢𝐬𝐭𝐚𝐤𝐞 in their first FDA or CE marking application: they focus obsessively on perfecting their technology while treating regulatory strategy as a checkbox to tick later. The consequences? Devastating delays that can kill promising companies: - Brilliant AI-powered diagnostic tools delayed by 18+ months - Funding rounds missed due to extended timelines - Competitive advantages lost to better-prepared competitors - Technical debt accumulated from retrofitting compliance Here's what separates the winners from the casualties: ❌ 𝐅𝐚𝐢𝐥𝐢𝐧𝐠 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: Build first, regulate later - Develop features without considering regulatory pathways - Scramble to create documentation post-development - Face costly redesigns to meet compliance requirements - Burn through runway during extended review periods ✅ 𝐒𝐮𝐜𝐜𝐞𝐬𝐬𝐟𝐮𝐥 𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬: Integrate regulatory thinking from day one - Map regulatory requirements before writing code - Design clinical validation into product development - Build Quality Management Systems alongside technology - Treat regulators as partners, not obstacles The reality is harsh: regulation isn't a hurdle to overcome after innovation—it IS part of innovation in healthcare. The FDA and Notified Bodies aren't just checking boxes; they're ensuring your brilliant technology actually helps patients safely. At Complear, we've seen this transformation happen when startups shift their mindset from "regulation vs. innovation" to "regulation-driven innovation." The companies that grasp this early don't just survive regulatory review—they thrive because of it. 𝐓𝐡𝐞 𝐪𝐮𝐞𝐬𝐭𝐢𝐨𝐧 𝐢𝐬𝐧'𝐭 𝐰𝐡𝐞𝐭𝐡𝐞𝐫 𝐲𝐨𝐮'𝐥𝐥 𝐟𝐚𝐜𝐞 𝐫𝐞𝐠𝐮𝐥𝐚𝐭𝐨𝐫𝐲 𝐜𝐡𝐚𝐥𝐥𝐞𝐧𝐠𝐞𝐬—𝐢𝐭'𝐬 𝐰𝐡𝐞𝐭𝐡𝐞𝐫 𝐲𝐨𝐮'𝐥𝐥 𝐛𝐞 𝐩𝐫𝐞𝐩𝐚𝐫𝐞𝐝 𝐟𝐨𝐫 𝐭𝐡𝐞𝐦. Are you building your regulatory strategy alongside your technology, or are you setting yourself up for an 18-month delay? #MedTech #Regulation #FDA #CEMarking #AIinHealthcare #MedicalDevices #RegulatoryStrategy

𝗢𝗻𝗲 𝗱𝗲𝘃𝗶𝗰𝗲. 𝗘𝗶𝗴𝗵𝘁 𝗺𝗮𝗿𝗸𝗲𝘁𝘀. 𝗘𝗶𝗴𝗵𝘁 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝗷𝗼𝘂𝗿𝗻𝗲𝘆𝘀. The science may be universal. Regulation is not. If you’re building a medical device for global markets, your regulatory strategy is not a compliance task — it’s a growth decision. 𝗛𝗲𝗿𝗲’𝘀 𝘁𝗵𝗲 𝗿𝗲𝗮𝗹𝗶𝘁𝘆 𝗮𝗰𝗿𝗼𝘀𝘀 𝗺𝗮𝗷𝗼𝗿 𝗺𝗮𝗿𝗸𝗲𝘁𝘀: 🇺🇸 USA – FDA Class I–III | 510(k), De Novo, PMA Data-heavy, precedent-driven, clinically rigorous. 🇪🇺 EU – MDR Class I–III | CE Marking via Notified Bodies Higher clinical expectations, limited NB capacity. 🇨🇦 Canada – Health Canada Class I–IV | MDSAP critical Often leveraged alongside FDA strategy. 🇦🇺 Australia – TGA ARTG inclusion Strong alignment with CE pathways. 🇨🇳 China – NMPA Local testing and clinical data often required. 🇮🇳 India – CDSCO Rapidly evolving regulatory framework. 🇧🇷 Brazil – ANVISA Local representation and Portuguese documentation mandatory. 𝗛𝗲𝗿𝗲’𝘀 𝘄𝗵𝗮𝘁 𝗜’𝘃𝗲 𝗹𝗲𝗮𝗿𝗻𝗲𝗱 𝘄𝗼𝗿𝗸𝗶𝗻𝗴 𝗮𝗰𝗿𝗼𝘀𝘀 𝗨𝗦 𝗮𝗻𝗱 𝗨𝗞 𝗿𝗲𝗴𝘂𝗹𝗮𝘁𝗼𝗿𝘆 𝘀𝘆𝘀𝘁𝗲𝗺𝘀: Startups fail not because their product is weak — but because their regulatory sequencing is reactive. 𝗦𝗺𝗮𝗿𝘁 𝗰𝗼𝗺𝗽𝗮𝗻𝗶𝗲𝘀: • Design regulatory pathways during product development • Align clinical data with multiple jurisdictions • Sequence markets strategically • Treat regulatory as valuation architecture Regulatory maturity reduces risk. Strategic sequencing increases enterprise value. Global expansion is engineered — not improvised. If you're building for multiple markets, which region are you prioritizing first — and why? Mahesh Uppara, MBA NovintiX #MedTech #MedicalDevices #RegulatoryAffairs #FDA #MDR #GlobalHealth

Product development leaders, still bolting on compliance? Proving regulatory compliance at the end of a project is a high-stakes gamble. A single gap can stall delivery, trigger costly delays, or block market entry altogether. One leading electronics manufacturer learned this the hard way. Their products sat on the docks for two months, costing an estimated €110 million, all while they scrambled to prove compliance. Compliance works best when it’s part of the design, not an afterthought. Here’s a 3-step framework to integrate it from the start: 1. Map Requirements Early. Identify all relevant regulations at project kickoff, linking them directly to your product specifications. 2. Embed in PLM. Connect these identified requirements to specific materials, components, and assemblies within your Product Lifecycle Management (PLM) system. 3. Validate Continuously. Leverage your PLM to automatically validate compliance as design decisions are made, ensuring real-time adherence.

🔎 Key Regulatory Strategies for Risk-Managed New Product Development for Biologicals Developing biological products is inherently complex due to their structural diversity, process dependency, and evolving regulatory expectations. A proactive, risk-managed regulatory strategy is essential to accelerate development, reduce uncertainty, and ensure patient safety. Here are key focus areas to enable regulatory success: ✅ 1️⃣ Define Clear Regulatory Pathways Early Understand regional requirements (FDA, EMA, PMDA, etc.) and classify your product to determine pathway, timelines, and data needs—including expedited programs where applicable. ✅ 2️⃣ Establish CMC & Quality Foundations from Day-1 Biologicals depend heavily on manufacturing consistency. Early definition of CQAs, CPPs, control strategies, and comparability frameworks minimizes downstream rework and delays. ✅ 3️⃣ Utilize Risk-Based Product Development (ICH Q8–Q12) Adopt QbD to identify and mitigate critical risks across process/analytical development, ensuring robust product understanding and regulatory confidence. ✅ 4️⃣ Build a Strong Analytical & Characterization Strategy Advanced techniques help define product attributes critical to safety and efficacy. A lifecycle analytical plan supports comparability, tech transfer, & post-approval changes. ✅ 5️⃣ Prioritize Clinical–CMC Alignment Seamless integration between clinical and CMC enables stage-appropriate control strategies, reliable supply, and efficient scale-up without delaying clinical milestones. ✅ 6️⃣ Engage Early & Frequently with Global Health Authorities Regulatory consultations enable alignment on development plans, platform technologies, assay strategy, and innovative approaches—significantly reducing uncertainties. ✅ 7️⃣ Invest in Robust Risk & Change Management Systems Structured risk evaluation and proactive change control enable efficient adaptation during lifecycle management and post-approval expansion. ✅ 8️⃣ Plan for Lifecycle & Global Expansion Early Global strategy, regional regulatory landscapes, post-approval requirements, and supply-chain scalability should be built into early development planning. ✨ Bottom Line: A proactive, risk-based regulatory strategy—from discovery to lifecycle management—supports efficient development, helps avoid late-stage surprises, and ensures timely patient access to innovative biological therapies.

Six months behind. Legally mandated deadline. Failure meant regulatory penalties, audits, & legal exposure. No pressure. A regulatory compliance program was supposed to start 12 months before the deadline. But when I stepped in, it hadn’t even begun. Six months had already been lost. The project was stuck in a dangerous loop: > Regulatory language was vague and open to interpretation > Teams were resisting the effort > Requirements weren’t defined > Leadership alignment didn’t exist > No one owned the path forward Meanwhile the legal deadline wasn’t moving. This wasn’t a project. It was a potential regulatory crisis. So the first step wasn’t planning. It was stabilization. The program required someone operating across multiple roles simultaneously: > Program recovery > Requirements translation > Architectural coordination, > Executive alignment under extreme time pressure. I shifted into recovery mode & rebuilt the program from the ground up. 1️⃣Rapid stakeholder mobilization We brought legal, architecture, engineering, & business leaders together to translate regulatory language into clear tech & operational requirements. Ambiguity had been the blocker. Clarity unlocked execution. 2️⃣Adaptive governance The teams involved operated in very different delivery models, & required direct executive alignment. Instead of forcing a framework, I built an adaptive governance structure that connected teams & ELT through: > Executive communication and decision checkpoints > A formal C-suite SteerCo > Clear escalation paths > Shared milestones tied to the regulatory deadline This removed fragmentation, ensuring technical execution & executive risk management stayed aligned. 3️⃣Iterative requirements refinement Regulatory language rarely translates cleanly into systems. I ran structured refinement sessions to: > Identify compliance requirements > Validate technical feasibility > Architect controls that satisfied both regulatory & operational needs This turned vague mandates into executable workstreams. 4️⃣Non-negotiable approval gates Under extreme timeline pressure, teams often skip validation. We did the opposite. Critical approvals were built into the program to ensure: > Compliance alignment > Architectural integrity > Audit defensibility Speed without rigor would have created bigger risks later. THE RESULT Despite starting six months late, the program delivered before the legal deadline. > Zero regulatory penalties > Zero audit defects > No legal exposure > No additional budget required The difference wasn’t working harder. It was turning regulatory ambiguity into executable workstreams & decisions. And the biggest risk? It wasn’t the timeline.  It was lack of ownership. Leadership isn’t about managing tasks. It’s about creating clarity fast enough for the organization to execute. And once someone owns the problem, translates the requirements & aligns leadership… Execution follows. ___  ♻️ Repost 🔔 Follow Elizabeth Dworkin